QT Imaging, Inc. is a public (NASDAQ: QTI) medical device company engaged in the research, development, and commercialization of innovative body imaging systems using low energy sound.
The QT Imaging Breast Acoustic CT™ System, featuring the trademarked Breast ACT™ technology, is our first scanner and represents a leap forward in patient-centric breast imaging. By harnessing the power of our advanced technology and eliminating the discomfort associated with traditional methods, we’re redefining the standard of care and empowering patients with a safer, more comfortable imaging experience.
Approximately 39 million women, in the United States, get mammograms every year (source: CDC). For every 1 woman with cancer, 19 more will be told they might have cancer when they don’t. The cost, time, and psychological distress takes an enormous toll. We exist to change the paradigm of breast imaging and to keep women from going through the trauma of this journey. It’s why the FDA granted clearance for the Breast ACT™ technology as an adjunct to mammography, and the National Institutes of Health (NIH) awarded over $15 million in funding (over multiple grants) for QT Imaging research, setting a new standard in breast imaging excellence.
The QT Imaging Breast Acoustic CT™ System is an advancement in breast imaging. Unlike traditional mammography, this state-of-the-art system offers numerous key advantages to a patient-centric approach. By eliminating uncomfortable breast compression, radiation exposure, and the need for contrast agents or injections, this innovative system prioritizes patient comfort and safety while delivering high-quality, high-resolution 3D images. Also, in overcoming the limitations of traditional methods, the QT Imaging scanner ensures consistent and reproducible image quality for patients with dense breast tissue or implants, backed by rigorous validation from the National Institutes of Health.